Loading clinical trials...

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

NCT00224315•Central Institute of Mental Health, Mannheim

View on ClinicalTrials.gov

Summary

We aim to compare the augmentation of clozapine with ziprasidone or risperidone in a randomized, prospective manner.

Detailed Description

Partial response of schizophrenic psychoses to a monotherapy with clozapine is a frequent problem of clinical psychiatry. Current problems are treatment resistant positive and/or negative symptoms, as well as side effects. Therefore, different strategies of augmentations have been applied. Based on successful experiences in case reports and results of other work groups, we aim to compare the augmentation of clozapine with ziprasidone or risperidone in a randomized, prospective manner.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Treatment resistant schizophrenic or schizoaffective disorder under therapy with clozapine,
•Age between 18 and 70,
•Informed consent

Exclusion Criteria

•No informed consent,
•Intolerance with respect to ziprasidone or risperidone,
•Contraindications with respect to these substances,
•Gravidity or missing anticonceptive safety
•Substance dependance (excluded nicotin)

Locations (1)

Central Institute of Mental Health, Department of Psychiatry,

Mannheim, Baden-Wurttemberg, Germany

Key Dates

Start Date

November 1, 2003

Completion Date

September 1, 2006

Last Updated

June 4, 2008

Enrollment

Estimated participants

Conditions

Schizophrenia, Schizoaffective Disorder

Interventions

ziprasidone

DRUG

risperidone

DRUG

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170

Schizophrenia, Schizoaffective Disorder

View study

TERMINATEDPHASE2

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640

Schizophrenia, Schizoaffective Disorder

View study

COMPLETEDPHASE1

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 4, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions